113 related articles for article (PubMed ID: 23395086)
1. Sustained autocrine induction and impaired negative feedback of osteoclastogenesis in CD14(+) cells of giant cell tumor of bone.
Avnet S; Salerno M; Zini N; Alberghini M; Gibellini D; Baldini N
Am J Pathol; 2013 Apr; 182(4):1357-66. PubMed ID: 23395086
[TBL] [Abstract][Full Text] [Related]
2. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone.
Atkins GJ; Kostakis P; Vincent C; Farrugia AN; Houchins JP; Findlay DM; Evdokiou A; Zannettino AC
J Bone Miner Res; 2006 Sep; 21(9):1339-49. PubMed ID: 16939392
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
4. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
5. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
6. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
8. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
9. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.
Wang T; Yin H; Wang J; Li Z; Wei H; Liu Z; Wu Z; Yan W; Liu T; Song D; Yang X; Huang Q; Zhou W; Xiao J
Oncotarget; 2015 Aug; 6(22):18980-96. PubMed ID: 26053181
[TBL] [Abstract][Full Text] [Related]
12. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone.
Roux S; Amazit L; Meduri G; Guiochon-Mantel A; Milgrom E; Mariette X
Am J Clin Pathol; 2002 Feb; 117(2):210-6. PubMed ID: 11863217
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.
Zheng MH; Fan Y; Wysocki SJ; Lau AT; Robertson T; Beilharz M; Wood DJ; Papadimitriou JM
Am J Pathol; 1994 Nov; 145(5):1095-104. PubMed ID: 7977641
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis.
Song D; Meng T; Xu W; Hou T; Lin Z; Yin H; Li B; Zhou L; Wang T; Han S; Fan T; Miao W; Liu M; Luo J; Zhou W; Li Z; Xiao J
Bone; 2015 Sep; 78():46-54. PubMed ID: 25956534
[TBL] [Abstract][Full Text] [Related]
15. Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclasts.
Rimondi E; Zweyer M; Ricci E; Fadda R; Secchiero P
Anat Rec (Hoboken); 2007 Jul; 290(7):838-45. PubMed ID: 17506059
[TBL] [Abstract][Full Text] [Related]
16. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
17. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
[TBL] [Abstract][Full Text] [Related]
18. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Wong KC; Kumta SM
Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
[TBL] [Abstract][Full Text] [Related]
20. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL).
Nicholson GC; Malakellis M; Collier FM; Cameron PU; Holloway WR; Gough TJ; Gregorio-King C; Kirkland MA; Myers DE
Clin Sci (Lond); 2000 Aug; 99(2):133-40. PubMed ID: 10918046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
